BioSpace News Archive

Genetown

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag (Updated)

The Institute for Clinical and Economic Review (ICER) concluded that even at a hefty lifetime cost of $2.5 million, gene therapies for hemophilia A and B are worth it.

September 15, 2022
·
3 min read
·
Tristan Manalac
Business

With $100M, Galvanize Absorbs Two Biotechs to Advance Electric Pulse Therapies

Gala Therapeutics and Galaxy Medical will be folded into Galvanize Therapeutics to continue to develop their electric pulse therapies for bronchitis, cardiac arrhythmias and solid tumors.

September 15, 2022
·
1 min read
·
Paul Elias
Drug Development

Pfizer Advances Vaccine Programs and Invests in Nimbus

Pfizer is leveraging its funding and experience with vaccines, developing its meningococcal, flu, and RSV vaccines. It also announced its venture investment in Nimbus Therapeutics.

September 15, 2022
·
3 min read
·
Mark Terry
Policy

Swiss Agency Probes Novartis over Potential Unlawful Patent Use

Novartis confirmed it is the subject of an investigation by the Swiss Competition Commission over possible unlawful patent use.

September 15, 2022
·
2 min read
·
Tristan Manalac
Genetic Link Identified for Chronic Fatigue Syndrome could Advance Treatment

Researchers at PrecisionLife say they have found a genetic link to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

September 15, 2022
·
2 min read
·
Paul Elias
Drug Development

In Cystic Fibrosis Failure, Eloxx Sees Silver Lining for Alport Syndrome

After reporting a failed clinical trial of ELX-02 for cystic fibrosis (CF), Eloxx Pharmaceuticals plans to shift its focus and use the drug to treat Alport syndrome, a rare kidney disease.

September 15, 2022
·
2 min read
·
Mark Terry
Policy

White House Reveals Details of Biomanufacturing Initiative to Put US on Top

Two days after unveiling an executive order to boost U.S. biomanufacturing, the White House unveiled plans that include $2 billion to support the initiative.

September 15, 2022
·
4 min read
·
Alex Keown
Business

Clinical Catch-Up: Neuron23, QIAGEN, Ocugen, BMS and More

There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.

September 15, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Carver Bio Plants Seed to Treat Viral Threats with CRISPR Cas13

With a distinct take on CRISPR, Carver Biosciences secured seed financing to support the development of RNA-targeting gene therapies aimed at RNA-based respiratory infectious diseases.

September 15, 2022
·
2 min read
·
Alex Keown
Policy

Congress Debates Reauthorization of FDA User Fees as Deadline Looms

The Sept. 30 deadline for Congress to reauthorize the FDA’s prescription drug user fee is looming, while advocates and detractors are debating the merits of the funding source.

September 15, 2022
·
3 min read
·
Alex Keown